1. Home
  2. ENSC vs SLE Comparison

ENSC vs SLE Comparison

Compare ENSC & SLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENSC
  • SLE
  • Stock Information
  • Founded
  • ENSC 2003
  • SLE 2014
  • Country
  • ENSC United States
  • SLE United States
  • Employees
  • ENSC N/A
  • SLE N/A
  • Industry
  • ENSC Biotechnology: Pharmaceutical Preparations
  • SLE Services-Misc. Amusement & Recreation
  • Sector
  • ENSC Health Care
  • SLE Consumer Discretionary
  • Exchange
  • ENSC Nasdaq
  • SLE Nasdaq
  • Market Cap
  • ENSC 9.8M
  • SLE 8.6M
  • IPO Year
  • ENSC N/A
  • SLE 2019
  • Fundamental
  • Price
  • ENSC $7.77
  • SLE $0.61
  • Analyst Decision
  • ENSC
  • SLE Strong Buy
  • Analyst Count
  • ENSC 0
  • SLE 2
  • Target Price
  • ENSC N/A
  • SLE $2.50
  • AVG Volume (30 Days)
  • ENSC 100.5K
  • SLE 87.2K
  • Earning Date
  • ENSC 03-14-2025
  • SLE 11-14-2024
  • Dividend Yield
  • ENSC N/A
  • SLE N/A
  • EPS Growth
  • ENSC N/A
  • SLE N/A
  • EPS
  • ENSC N/A
  • SLE N/A
  • Revenue
  • ENSC $4,421,404.00
  • SLE $22,266,000.00
  • Revenue This Year
  • ENSC $89.78
  • SLE N/A
  • Revenue Next Year
  • ENSC N/A
  • SLE $33.97
  • P/E Ratio
  • ENSC N/A
  • SLE N/A
  • Revenue Growth
  • ENSC 40.41
  • SLE N/A
  • 52 Week Low
  • ENSC $2.12
  • SLE $0.50
  • 52 Week High
  • ENSC $30.90
  • SLE $2.84
  • Technical
  • Relative Strength Index (RSI)
  • ENSC 50.09
  • SLE 44.60
  • Support Level
  • ENSC $6.75
  • SLE $0.56
  • Resistance Level
  • ENSC $9.57
  • SLE $0.76
  • Average True Range (ATR)
  • ENSC 0.73
  • SLE 0.08
  • MACD
  • ENSC -0.13
  • SLE -0.00
  • Stochastic Oscillator
  • ENSC 36.17
  • SLE 18.45

About ENSC Ensysce Biosciences Inc.

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

About SLE Super League Enterprise Inc.

Super League Enterprise Inc is the rocket ship to the metaverse. It is a creator and publisher of content experiences and media solutions across the globe's immersive platforms. Its solutions provide incomparable access to massive audiences that gather in immersive digital spaces to socialize, play, explore, collaborate, shop, learn and create. The company offers a complete range of development, distribution, monetization and optimization capabilities designed to engage users through dynamic, energized programs. It generates revenue from advertising including immersive game world and experience publishing and in-game media products, direct to consumer offers, including in-game items, e-commerce, game passes and ticketing and digital collectibles, and content and technology.

Share on Social Networks: